Deal of the Day — limited-time pharmacy picks!
Ruparib 200mg Tablet

Ruparib 200mg Tablet

Prescription requiredRx Required

Salt Composition: Rucaparib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

60 Tablets in Bottle

About The Product

Ovarian Cancer, Prostate cancer

Description

Ruparib 200mg tablet is a prescription based medication. It is used as the first line therapy in treatment of ovarian cancer and prostate cancer. Its active ingredient is Rucaparib which belongs to the drug class of PARP (poly ADP ribose polymerase) inhibitors. It works by preventing cancer cells from repairing their DNA, leading to cell death.

The medication is used to slow or stop cancer progression and help improve disease control in eligible patients. It is recommended to consult the doctor regarding the appropriate dosage and duration of the treatment or manage possible side effects before starting the medication.

​

Uses

  • Ovarian cancer and prostate cancer


Side Effects

  • Some of the medications show various side effects, patient also experiencing side effects while using Ruparib 200mg tablet.
  • Discuss the doctor if any of the symptoms persist or worsen. • Nausea, vomiting • Changes in the blood count • Shortness of breath • Tiredness • Rash • Constipation • Decrease in appetite • Diarrhea, indigestion • Severe anemia • Hypersensitivity reactions • Sepsis (blood infection) • Pneumonia

How To Use

  • Ruparib 200mg tablet should be taken with or without food but at the fixed time everyday to enhance the effectiveness of the treatment.
  • Never skip or stop taking the medication without consultation with a healthcare provider as the medicine can show the side effects or reduce treatment effectiveness if not taken as prescribed.
  • Do not double up the dose on the missed one in order to avoid complications during the treatment.

How It Works

  • Ruparib 200mg contains PARP inhibitor used in prostate and ovarian cancer that blocks the PARP enzyme involved ion DNA repair. Inhibition of PARP causes accumulation DNA damage in cancer cells.
  • Tumor cells with BRCA mutation cannot repair the damage and hence in that way It slow or stop the progression of cancer cells in the body.
    ​

Safety Advice

Alcohol
While taking Ruparib 200mg tablet, it is unknown whether alcohol is causing side effects or not. Doctor recommendation is necessary during the treatment.
Pregnancy
Pregnant women should consult the healthcare provider if it is safe to take Ruparib 200mg tablet. Dosage administration is necessary during the ongoing treatment.
Breast Feeding
Breastfeeding is not recommended in patients taking Ruparib tablet as the medication is passing through the breast which affects the baby in various ways.
Driving
Ruparib 200mg tablet causes dizziness and drowsiness, patient should avoid driving and operating machinery. Consult the healthcare professional if any of the symptoms persist.
Kidney
Kidney patients can use Ruparib 200mg tablet as it do not disrupt the kidney function but consultation is required from the doctor to help manage the treatment well.
Liver
Ruparib tablet is safe to use patient with liver disease. Dose adjustment should not be required while using the medication.

FAQs

Ruparib 200mg tablet is taken by the patient of prostate and ovarian cancer that is used as targeted therapy PARP inhibitor mainly for maintenance treatment in BRCA mutated cancers.​

References

  • Syed, Y. Y. (2017). Rucaparib: first global approval. Drugs, 77(5), 585-592. https://pubmed.ncbi.nlm.nih.gov/28247266/
  • Shirley, M. (2019). Rucaparib: a review in ovarian cancer. Targeted Oncology, 14(2), 237-246. https://pubmed.ncbi.nlm.nih.gov/30830551/
  • Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., ... & Bryce, A. H. (2023). Rucaparib or physician’s choice in metastatic prostate cancer. New England Journal of Medicine, 388(8), 719-732. https://pubmed.ncbi.nlm.nih.gov/36795891/
  • Balasubramaniam, S., Beaver, J. A., Horton, S., Fernandes, L. L., Tang, S., Horne, H. N., ... & Pazdur, R. (2017). FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation–associated advanced ovarian cancer. Clinical Cancer Research, 23(23), 7165-7170. https://pubmed.ncbi.nlm.nih.gov/28751443/
  • Liao, M., Beltman, J., Giordano, H., Harding, T. C., Maloney, L., Simmons, A. D., & Xiao, J. J. (2022). Clinical pharmacokinetics and pharmacodynamics of rucaparib. Clinical Pharmacokinetics, 61(11), 1477-1493. https://pubmed.ncbi.nlm.nih.gov/36107395/

Certified Content

Written By
Venika Choudhary

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By
Dr. Aditya Sarin

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026